ArticleCureus2025
Outcomes in Patients With Multiple Myeloma and Prescribed Urate-Lowering Therapy: A Propensity-Matched Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Multiple myeloma or MM is a plasma cell dyscrasia that causes monoclonal immunoglobulin accumulation and is associated with manifestations including hypercalcemia, anemia, bone pain, and renal dysfunction. Gout is also associated with electrolyte derangements that result in similar end-organ dysfunction. There is little information on outcomes in patients with both diagnoses. Methods Adult patients with MM were propensity-score matched according to age at index event, sex, demographics, and comorbidities. Patients were identified using the International Classification of Diseases (ICD)-10 codes through TriNetX's US Collaborative Network and sorted into cohorts based on the prescription of urate-lowering therapies (ULTs). Three ULTs, allopurinol, febuxostat, and rasburicase, were studied individually. Cohorts of patients with MM and any ULT and those with MM but no ULT were also included. Outcomes were followed for five years to assess the rates of acute kidney injury (AKI), dialysis initiation (HD), seizures, atrial fibrillation/atrial flutter (AF/AFL), ventricular fibrillation/ventricular tachycardia (VF/VT), and all-cause mortality. Results When compared to patients with MM with any ULT, the cohort of patients with MM and no ULT demonstrated significantly lower rates of HD (HR 0.74, 95% CI 0.671-0.815, p<0.0001), AF/AFL (HR 0.99, 95% CI 0.924-1.061, p<0.0001), VF/VT (HR 0.853, 95% CI 0.752-0.968, p=0.0066), and mortality (HR 1.012, 95% CI 0.965-1.065, p<0.0001). The MM with no allopurinol group demonstrated significantly reduced rates of AKI (HR 0.901, 95% CI 0.839-0.968, p=0.0007), HD (HR 0.715, 95% CI 0.633-0.807, p<0.0001), seizures (HR 1.029, 95% CI 0.868-1.219, p=0.0012), AF/AFL (HR 1.006, 95% CI 0.921-1.098, p<0.0001), VF/VT (HR 0.837, 95% CI 0.718-0.975, p=0.0024), and mortality (HR 0.919, 95% CI 0.868-0.974, p<0.0001) compared to the MM with allopurinol cohort. The MM with no febuxostat cohort showed significantly reduced rates of AF/AFL (HR 1.009, 95% CI 0.762-1.335, p=0.004) compared to the MM cohort with febuxostat. The MM with no rasburicase cohort had significantly reduced risk of AF/AFL (HR 0.861, 95% CI 0.582-1.275, p=0.0381) compared to the MM with rasburicase cohort. Conclusion ULTs may increase the risk of requiring HD, developing cardiac arrhythmia, and potentially mortality in patients with MM. There appear to be some ULT-specific relationships that warrant further exploration. These findings could be related to the electrolyte disturbances and end-organ dysfunction of MM being compounded by those of gout. Further research should be conducted to elucidate any relationship between these diagnoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.